257 related articles for article (PubMed ID: 28435325)
1. The clinical development of obinutuzumab for the treatment of follicular lymphoma.
Ma B; Ujjani C
Cancer Manag Res; 2017; 9():103-113. PubMed ID: 28435325
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
Herting F; Friess T; Bader S; Muth G; Hölzlwimmer G; Rieder N; Umana P; Klein C
Leuk Lymphoma; 2014 Sep; 55(9):2151-5160. PubMed ID: 24304419
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
Dhillon S
Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas.
Gabellier L; Cartron G
Ther Adv Hematol; 2016 Apr; 7(2):85-93. PubMed ID: 27054024
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
12. Impact of obinutuzumab alone and in combination for follicular lymphoma.
Sarraf Yazdy M; Cheson BD
Blood Lymphat Cancer; 2017; 7():73-83. PubMed ID: 31360086
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab for the treatment of indolent lymphoma.
Edelmann J; Gribben JG
Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
Klein C; Bacac M; Umana P; Fingerle-Rowson G
Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
16. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
Tobinai K; Klein C; Oya N; Fingerle-Rowson G
Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
[TBL] [Abstract][Full Text] [Related]
17. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL.
Chu Y; Awasthi A; Lee S; Edani D; Yin C; Hochberg J; Shah T; Chung TH; Ayello J; van de Ven C; Klein C; Lee D; Cairo MS
Oncotarget; 2020 Aug; 11(32):3035-3047. PubMed ID: 32850008
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
